

The FASEB Journal

Volume 7, 1993

PUBLICATIONS COMMITTEE

BETTY J. GAFFNEY, Chair
CAROLYN D. BERDANIER
KATHRYN CALAME
ANN GINSBURG

WILLIAM P. JOLLIE
RICHARD E. PAGAND
ROBERT R. RUFFOLO, JR.
THOMAS W. TILLACK

JOHN A. WILLIAMS
FRANK W. FITCH, *ex officio*
MICHAEL J. JACKSON, *ex officio*

EDITORIAL BOARD

WILLIAM J. WHELAN, Editor-in-Chief
KARE BERG
ROBERT M. BERNE
PIET BORST
PIERRE CHAMBON
GWEN V. CHILDS
BRIAN F. C. CLARK
WALTER COLLI
THOMAS S. EDGINGTON
RICHARD A. FREEDLAND
RAY W. FULLER
JOHN W. FUNDER
MICHAEL W. GRAY
PAUL GREENGARD

WAYNE A. HENDRICKSON
SARAH HITCHCOCK-DEGREGORI
ANN L. HUBBARD
BERNARD JEANRENAUD
THOMAS J. KINDT
TADAMITSU KISHIMOTO
GEORGE KLEIN
HANS L. KÖRNBERG
BYRON G. LANE
KATHRYN F. LANOUE
CHARLES P. LEBLOND
LANCE A. LIOTTA
VINCENT MASSEY
JAMES A. OLSON

RODOLFO PAOLETTI
MARY LOU PARDUE
ARMANDO J. PARODI
IRA H. PASTAN
FRANKLYN G. PRENDERGAST
MARYVONNE ROSSENEU
MARGARITA SALAS
DANTE G. SCARPELLI
MICHAEL SELA
KONSTANTIN G. SKRYABIN
RUPERT TIMPL
CHEN-LU TSOU
ELLEN S. VITETTA

STAFF

LEWIS I. GIDEZ, *Executive Editor*
SANDRA W. JACOBSON, *Assistant Executive Editor*
KENDALL SITES, *Copy Editor*

Applicants: David J. Pinsky
U.S. Serial No.: 09/374,586
Filed: August 13, 1999
Group Art Unit: 1633

Exhibit 26

FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY
9650 Rockville Pike, Bethesda, MD 20814

Copyright © 1993 by
FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY
Printed in the United States of America
by LANCASTER PRESS, Lancaster, Pennsylvania

Contents of Volume 7

Number 1, JANUARY 1993

Editorial

- Sol's World, the RNA World, Our World. W. F. Doolittle . . . 1

News

- In Brief . . . 3

Overview

- The new age of RNA. M. W. Gray and R. Cedergren . . . 4

Reviews

RNA as a Catalyst

- Recent studies of ribonuclease P. S. Altman, L. Kirsebom, and S. Talbot . . . 7
- Group I and group II introns. R. Saldanha, G. Mohr, M. Belfort, and A. M. Lambowitz . . . 15
- Self-cleaving catalytic RNA. D. M. Long and O. C. Uhlenbeck . . . 25
- How many catalytic RNAs? Ions and the Cheshire cat conjecture. M. Yarus . . . 31

RNA Processing

- Trans-splicing of pre-mRNA in plants, animals, and protists. L. Bonen . . . 40
- Small nuclear RNAs in messenger RNA and ribosomal RNA processing. I. W. Mattaj, D. Tollervey, and B. Séraphin . . . 47
- RNA editing in kinetoplastid mitochondria. S. L. Hajduk, M. E. Harris, and V. W. Pollard . . . 54
- RNA editing in plant mitochondria and chloroplasts. M. W. Gray and P. S. Covello . . . 64

RNA in Protein Synthesis

- Transfer RNA identity. W. H. McClain . . . 72
- Recognition of tRNAs by aminoacyl-tRNA synthetases. J. Cavarelli and D. Moras . . . 79
- tRNA-rRNA interactions and peptidyl transferase. H. F. Noller . . . 87

RNA Structure

- Chemically modified RNA: approaches and applications. O. Heidenreich, W. Pieken, and F. Eckstein . . . 90
- Modeling the three-dimensional structure of RNA. D. Gautheret and K. Cedergren . . . 97

RNA in Evolution

- In vitro selection and evolution of RNA: applications for catalytic RNA, molecular recognition, and drug discovery. J. M. Burke and A. Berzal-Herranz . . . 106
- Ribosomal RNA: a key to phylogeny. G. J. Olsen and C. R. Woese . . . 113

Research Communications

RNA as a Catalyst

- Promiscuity and compensation mutations to evaluate essential stem structures of genomic HDV ribozyme. P. K. R. Kumar, Y.-A. Suh, K. Taira, and S. Nishikawa . . . 124

- Modification interference analysis of a self-cleaving RNA from hepatitis delta virus. M. G. Belinsky, E. Britton, and G. Dinter-Gottlieb . . . 130

- Theoretical analyses on the role of Mg²⁺ ions in ribozyme reactions. T. Uchimaru, M. Uebayasi, K. Tanabe, and K. Taira . . . 137

RNA Processing

- Multiple exoribonucleases are required for the 3' processing of *Escherichia coli* tRNA precursors in vivo. N. B. Reuven and M. P. Deutscher . . . 143

- Synthesis and regulation of trans-mRNA encoding the immunoglobulin heavy chain. A. Shimizu and T. Honjo . . . 149

- Mis-splicing yields circular RNA molecules. C. Cocquerelle, B. Mestrez, D. Hétiuin, and B. Bailleul . . . 155

RNA in Protein Synthesis

- Clustering of modified nucleotides at the functional center of bacterial ribosomal RNA. R. Brimacombe, P. Mitchell, M. Oussaid, K. Stade, and D. Bochkariou . . . 161

- Energy cost of proofreading in the charging of methionine tRNAs in *Escherichia coli*. H. Jakubowski . . . 168

- The 5' proximal helix of 16S rRNA is involved in the binding of streptomycin to the ribosome. R. Pinard, C. Payant, P. Melançon, and L. Brakier-Gingras . . . 173

- Chemical evidence for domain assembly of the *Escherichia coli* 30S ribosome. C. J. Weitzmann, P. R. Cunningham, K. Nurse, and J. Ofengand . . . 177

RNA Structure

- In vitro dimerization of HIV-2 leader RNA in the absence of PuGGAPuA motifs. B. Berkhout, B. B. Oude Essink, and I. Schoneveld . . . 181

- Gap-scan deletion analysis of *Bacillus subtilis* RNase P RNA. D. S. Waugh and N. R. Pace . . . 188

- 5S rRNA modification in the hyperthermophilic archaea *Sulfolobus solfataricus* and *Pyrodicticum occultum*. E. Bruenger, J. A. Kowalak, Y. Kuchino, J. A. McCloskey, H. Mizushima, K. O. Stetter, and P. F. Crain . . . 196

- Selective enrichment of RNA species for tight binding to *Escherichia coli* rho factor. D. Schneider, L. Gold, and T. Platt . . . 201

- Secondary structure of RNase MRP RNA as predicted by phylogenetic comparison. M. E. Schmitt, J. L. Bennett, D. J. Dairaghi, and D. A. Clayton . . . 208

- HIV-1 TAR RNA-binding proteins control TAT activation of translation in *Xenopus* oocytes. M. Braddock, R. Powell, A. D. Blanchard, A. J. Kingsman, and S. M. Kingsman . . . 214

RNA in Evolution

- Unique phylogenetic position of Diplomonadida based on the complete small subunit ribosomal RNA sequence of *Giardia ardeae*, *G. muris*, *G. duodenalis* and *Hexamita* sp. H. van Keulen, R. R. Gutell, M. A. Gates, S. R. Campbell, S. L. Erlandsen, E. L. Jarroll, J. Kulda, and E. A. Meyer . . . 223

- Bacterial diversity in a soil sample from a subtropical Australian environment as determined by 16S rDNA analysis. E. Stackebrandt, W. Liesack, and B. M. Goebel . . . 232

Errata

- Glucose and diabetic vascular disease. N. B. Ruderman, J. R. Williamson, and M. Brownlee . . . 237

- Thrombospondins: structure and regulation of expression. P. Bornstein . . . 237

25 Years Ago

- Anticipating an RNA World. Some Past Speculations on the Origin of Life: Where Are They Today? L. E. Orgel and F. H. C. Crick . . . 238

- Calendar . . . 240

- Book List . . . 244

- Information for Authors . . . 245

- Employment Opportunities . . . 249

- New Products . . . 252

Number 2, FEBRUARY 1993

Editorial

- Emeritus Professors Can, Assistant Professors Mustn't. V. R. Potter . . . 255

News & Features

- In Brief . . . 257

- Previews of Experimental Biology '93 . . . 259

Special Feature:

- Electromagnetic Field Interactions with Biological Systems. A. H. Frey . . . 272

Reviews

- Aminoacylation of RNA oligonucleotides: minimalist structures and origin of specificity. K. Musier-Forsyth and P. Schimmel . . . 282

Corticotropin-releasing factor: an antireproductive hormone of the testis. <i>M. L. Dufau, J. C. Tinajero, Fabbri</i>	299
von Willebrand factor. <i>Z. M. Ruggeri Ware</i>	308
Cellular metabolism and activation of retinoids: roles of cellular retinoid-binding proteins. <i>A. C. Ross</i>	317
Intracellular cyclic GMP receptor proteins. <i>T. M. Lincoln and T. L. Cornwell</i>	328
New insights on mammalian phospholipase A ₂ (s); comparison of arachidonoyl-selective and -nonselective enzymes. <i>R. J. Mayer and L. A. Marshall</i>	339
Methodology	
Measurement of nitric oxide in biological models. <i>S. Archer</i>	349
Research Communications	
Overexpression of mitochondrial manganese superoxide dismutase promotes the survival of tumor cells exposed to interleukin-1, tumor necrosis factor, selected anticancer drugs, and ionizing radiation. <i>K. Hirose, D. L. Longo, J. J. Oppenheim, and K. Matsushima</i>	361
A 1-hour pulse with IL-1 β induces formation of nitric oxide and inhibits insulin secretion by rat islets of Langerhans: evidence for a tyrosine kinase signaling mechanism. <i>J. A. Corbett, M. A. Sweetland, J. R. Lancaster, Jr., and M. L. McDaniel</i>	369
Novel <i>Drosophila</i> laminin A chain reveals structural relationships between laminin subunits. <i>A. J. MacKrell, M. Kusch-Gullberg, K. Garrison, and J. H. Fessler</i>	375
FASEB or Federation? <i>F. W. Putnam</i>	382
50 Years Ago	
From Antigen to Antibody. <i>F. W. Putnam</i>	383
Calendar	385
BookList	386
Employment Opportunities	387
New Products & Literature	389

Numbers 3 and 4—Abstracts **VOIR AUTRE PÉRIODE**

Number 5, MARCH 1993

Editorial	
Increasing Opportunities for Women Benefits the Entire Research Community. <i>A. J. Wolfson</i>	393
News & Features	
BioBits	395
Special Feature:	
Effects of spaceflight on the musculoskeletal system: NIH and NASA future directions. <i>R. Rabin, S. L. Gordon, R. W. Lynn, P. W. Todd, M. A. B. Frey, and F. M. Sulzman</i>	396
Reviews	
The design and application of residualizing labels for studies of protein catabolism. <i>S. R. Thorpe, J. W. Baynes, and Z. C. Chronos</i>	399
Coaggregation: specific adherence among human oral plaque bacteria. <i>P. E. Kolenbrander, N. Ganeshkumar, F. J. Cassels, and C. V. Hughes</i>	406
Is dehydroepiandrosterone an antiobesity agent? <i>C. D. Berdanier, J. A. Parente, Jr., and M. K. McIntosh</i>	414
Role of the CD45 tyrosine phosphatase in signal transduction in the immune system. <i>G. A. Koretzky</i>	420
Control of gene expression by lipophilic hormones. <i>R. R. Reichel and S. T. Jacob</i>	427
Idiotypes: structure and immunogenicity. <i>N. S. Greenspan and C. A. Bona</i>	437
Synthesis of vitamin K-dependent proteins. <i>J. W. Suttie</i>	445
Research Communications	
Ca ²⁺ antagonists inhibit DNA fragmentation and toxic cell death	

<i>M. W. Gurule, R. D. Yarkin, and G. B. Corcoran</i>	453
Expression of the dual phenolase/ τ -crystallin gene in transgenic mice. <i>R. Y. Kim and Wistow</i>	464
Delayed internucleosomal DNA fragmentation in programmed cell death. <i>Z. F. Zakari, D. Quaglini, T. Latham, and R. A. Lockshin</i>	470
Enflurane inhibits NMDA, AMPA, and kainate-induced currents in <i>Xenopus</i> oocytes expressing mouse and human brain mRNA. <i>L.-H. Lin, L. L. Chen, and R. A. Harris</i>	479
50 Years Ago	
Studies on Enzyme Inhibition—50 Years Ago. <i>V. R. Potter</i>	486
Calendar	488
BookList	489
Employment Opportunities	490
New Products & Literature	500
Number 6, APRIL 1993	
Editorial	
Nutrients and the Human Genome: New Frontiers for the Next Century. <i>P. P. Nair</i>	501
News & Features	
Dr. Kinyoun's Legacy: the International Dimensions of the National Institutes of Health. <i>P. E. Schambra</i>	503
Reviews	
Understanding cytochrome <i>c</i> function: engineering protein structure by semisynthesis. <i>C. J. A. Wallace</i>	505
Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis. <i>A. J. Marcus and L. B. Safer</i>	516
Endothelial cell gene expression in response to injury. <i>M. E. Gerritsen and C. M. Bloor</i>	523
Progress toward oligonucleotide therapeutics: pharmacodynamic properties. <i>S. T. Crooke</i>	533
Glycoprotein biosynthesis in yeast. <i>A. Herscovics and P. Orlean</i>	540
Choline phospholipids: signal transduction and carcinogenesis. <i>S. H. Zeisel</i>	551
Aspects of life development at deep sea hydrothermal vents. <i>F. Gaill</i>	558
Research Communications	
Identification of increased nitric oxide biosynthesis during pregnancy in rats. <i>K. P. Conrad, G. M. Joffe, H. Kruszyna, R. Kruszyna, L. G. Rochelle, R. P. Smith, J. E. Chavez, and M. D. Mosher</i>	566
Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. <i>A. R. Thierry, D. Vigé, S. S. Coughlin, J. A. Belli, A. Drischilo, and A. Rahman</i>	572
Cyclic AMP potentiates glucocorticoid-induced endogenous endonuclease activation in thymocytes. <i>D. J. McConkey, S. Orrenius, S. Okret, and M. Jondal</i>	580
Proline-mediated enhancement of hepatocyte function in a collagen gel sandwich culture configuration. <i>J. Lee, J. R. Morgan, R. G. Tompkins, and M. L. Yarmush</i>	586
Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. <i>R. M. Ransohoff, T. A. Hamilton, M. Tani, M. H. Stoler, H. E. Shick, J. A. Major, M. L. Estes, D. M. Thomas, and V. K. Tuohy</i>	592
50 Years Ago	
Brain Metabolism, "Ferrin," and Non-Carbohydrate Oxidation. <i>B. Libet</i>	601
Calendar	603
BookList	608
Employment Opportunities	609
New Products & Literature	613

453	Editorial	
464	Let our Voices Be Heard and Amplified. The Time Is Now!	
470	S. Chien	615
479	News & Features	
	Karl F. Heumann	618
486	BioBits	618
488	Special Feature:	
489	On Giraffes and Peer Review. D. R. Forsdyke	619
490	Reviews	
500	The reductive pentose phosphate cycle for photosynthetic CO ₂ assimilation: enzyme modulation. R. A. Wolosiuk, M. A. Ballicora, and K. Hagelin	622
	Perianesthetic thermoregulation and heat balance in humans. D. I. Sessler	638
	Growth hormone-releasing hormone and interleukin-1 in sleep regulation. J. M. Krueger and F. Obál, Jr.	645
	Spermidine/spermine N ¹ -acetyltransferase—the turning point in polyamine metabolism. R. A. Casero, Jr. and A. E. Pegg	653
501	Lysine 2,3-aminomutase: is adenosylmethionine a poor man's adenosylcobalamin? P. A. Frey	662
	Stereochemistry of a multistep/biparite methyl transfer reaction: thymidylate synthase. R. M. Stroud and J. S. Finer-Moore	671
503	Sensory circumventricular organs and brain homeostatic pathways. A. K. Johnson and P. M. Gross	678
	Research Communications	

505	Modulation of the activity and subcellular distribution of protein tyrosine kinases in human neutrophils by phorbol esters. M. Guadry, A. C. Caon, and P. H. Naccache	687
516	Structure-function properties of human platelet 12-lipoxygenase: chimeric enzyme and in vitro mutagenesis studies. X.-S. Chen and C. D. Funk	694
523	65-kDa protein binds to destabilizing sequences in the IFN- β mRNA coding and 3' UTR. N. B. K. Raj and P. M. Pitha	702
533	50 Years Ago	
540	Energy-Dependent Transphosphorylation over 50 Years. H. M. Kalckar and D. B. Ullrey	711
551	Calendar	713
558	BookList	714
	Employment Opportunities	715
	New Products & Literature	720

Number 9, JUNE 1993

572	Editorial	
	Principles of Scientific Management Sir Walter Bodmer	723
580	News & Features	
	BioBits	725
	Highlights - ASPET Annual Meeting	727
586	Special Features:	
	Passing or failing? Is biomedical science meeting national needs? D. L. Brautigan	730
592	ASBMB Educational Affairs Committee studies undergraduate biochemistry and molecular biology degrees. J. K. Zimmerman and R. F. Boyer	733
	Serial Review	
601	Introduction to serial Reviews: the extracellular matrix I. J. F. Woessner, Jr.	735
603	Multi-faceted regulation of cell differentiation by extracellular matrix. C. Q. Lin and M. J. Bissell	737
609	State-of-the-Art Reviews	
613	Engineering proteins for nonnatural environments. F. H. Arnold	744

	emerging concepts in the Ras superfamily of GTP-binding proteins. G. M. Bokoch and C. J. Der	750
	Site-specific genetic recombination: hops, flips, and flops. P. D. Sadowski	760
	Molecular and functional diversity of mammalian G _s -stimulated adenylyl cyclases. R. Iyengar	768
	Methodology Reviews	
	Strategies for nonradioactive methods in the localization of phosphorylated amino acids in proteins. H. E. Meyer, B. Eisermann, M. Heber, E. Hoffmann-Posorske, H. Korte, C. Weigt, A. Wegner, T. Hutton, A. Donella-Deana, and J. W. Perich	776
	Modeling protein structures: construction and their applications. C. S. Ring and F. E. Cohen	783
	Research Communications	
	Glucose metabolism in transgenic mice containing a chimeric P-enolpyruvate carboxykinase/bovine growth hormone gene. A. Valera, J. E. Rodriguez-Gil, J. S. Yun, R. W. Hanson, and F. Bosch	791
	Evidence for direct effect of magnetic fields on neurite outgrowth. C. F. Blackman, S. G. Benane, and D. F. House	801
	Erratum	806
	50 Years Ago	
	Sammy Wright. E. J. M. Campbell	807
	Calendar	809
	BookList	810
	Employment Opportunities	811
	New Products & Literature	815

Number 10, JULY 1993

	Editorial	
	Tumor Suppressor Genes—The Hope. W.-H. Lee	819
	News	
	BioBits	820
	Overview	
	Genes that can antagonize tumor development. G. Klein	821
	Reviews	
	TUMOR SUPPRESSION AND REVERSION	
	Tumor suppressor genes studied by cell hybridization and chromosome transfer. M. J. Anderson and E. J. Stanbridge	826
	Mechanisms of reversion. M. Noda	834
	THE RETINOBLASTOMA (Rb) GENE	
	The retinoblastoma gene: role in cell cycle control and cell differentiation. K. G. Wiman	841
	Speculations on the roles of Rb1 in tissue-specific differentiation, tumor initiation, and tumor progression. P. A. Hamel, R. A. Phillips, M. Muncaster, and B. L. Gallie	846
	THE p53 GENE	
	A comparison of the biological activities of wild-type and mutant p53. G. P. Zambetti and A. J. Levine	855
	INTERACTIONS BETWEEN VIRAL PROTEINS AND Rb OR p53	
	Interactions between SV40 large-tumor antigen and the growth suppressor proteins pRB and p53. J. W. Ludlow	866
	Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes. K. Vousden	872
	Interaction of adenoviral proteins with pRB and p53. E. Moran	880
	OTHER TUMOR SUPPRESSOR GENES	
	The role of WT1 in Wilms tumorigenesis. M. J. Coppes, C. E. Campbell, and B. R. G. Williams	886
	The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. F. J. Rauscher III	896
	ErbA: tumor suppressor turned oncogene? K. Damm	904

The role of gene mutations in the genesis of familial cancers. <i>C. Eng and B. A. J. Ponder</i>		
Multiple steps in carcinogenesis involving alterations of multiple tumor suppressor genes. <i>J. Fukuda and T. Sugimura</i>		
Gene and chromosomal alterations associated with the development of human gliomas. <i>V. P. Collins and C. D. James</i>		
Research Communications		
RB1 protein in normal and malignant human colorectal tissue and colon cancer cell lines. <i>A. A. Ali, J. N. Marcus, J. P. Harvey, R. Roll, C. P. Hodgson, D. M. Wildrick, A. Chakraborty, and B. M. Boman</i>		
Genetic background alters the spectrum of tumors that develop in p53-deficient mice. <i>M. Harvey, M. J. McArthur, C. A. Montgomery, Jr., A. Bradley, and L. A. Donehower</i>		
Dosage-dependent dominance over wild-type p53 of a mutant p53 isolated from nasopharyngeal carcinoma. <i>Y. Sun, Z. Dong, K. Nakamura, and N. H. Colburn</i>		
Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect. <i>K. Bhatia, W. Goldschmidt, M. Gutierrez, G. Gaidano, R. Dalla-Favera, and I. Magrath</i>		
Identification of mutations in p53 that affect its binding to SV40 large T antigen by using the yeast two-hybrid system. <i>B. Li and S. Fields</i>		
METHODOLOGY COMMUNICATIONS		
Identification by differential display of alpha 6 integrin as a candidate tumor suppressor gene. <i>R. Sager, A. Anisowicz, M. Neveu, P. Liang, and G. Sotiropoulou</i>		
Synthetic retrotransposon vectors for gene therapy. <i>A. K. Chakraborty, M. A. Zink, B. M. Boman, and C. P. Hodgson</i>		
24 Years Ago		
How Tumour Suppressor Genes Were Discovered. <i>H. Harris</i>		
Calendar		
BookList		
Employment Opportunities		
New Products & Literature		
Number 11, AUGUST 1993		
Editorial		
We Try Harder. <i>W. J. Whelan</i>		
News & Features		
BioBits		
Special Feature:		
Science odyssey: bringing our schools aboard.		
Serial Review		
Extracellular Matrix 2: Role of extracellular matrix molecules and their receptors in the nervous system. <i>K. A. Venstrom and L. F. Reichardt</i>		
Reviews		
Activation of neutrophil leukocytes: chemoattractant receptors and respiratory burst. <i>M. Baggiolini, F. Boulay, J. A. Badwey, and J. T. Curnutte</i>		
Intracellular parasitism of <i>Legionella</i> and signaling in eukaryotic cells. <i>Y. F. Belyi</i>		
Bacterial bioluminescence: organization, regulation, and application of the <i>lux</i> genes. <i>E. A. Meighen</i>		
Integral membrane heparan sulfate proteoglycans. <i>G. David</i>		
Pericyte physiology. <i>D. Shepro and N. M. L. Morel</i>		
Regulation of the long-chain carnitine acyltransferases. <i>P. S. Brady, R. R. Ramsay, and L. J. Brady</i>		
Research Communications		
Nicotine inhibition of apoptosis suggests a role in tumor promotion. <i>S. C. Wright, J. Zhong, H. Zheng, and J. W. Larrick</i>		
Seasonal variations in antibody-dependent cellular cytotoxicity regulation by melatonin. <i>M. Giordano, M. Vermeulen, and M. S. Palermo</i>		
Somatostatin analog lanreotide inhibits myocyte replication and several growth factors in allograft arteriosclerosis. <i>P. Häyry, A. Räsänen, J. Ustinov, A. Mennander, and T. Paavonen</i>		
Methodology		
Microencapsulation of recombinant cells: a new delivery system for gene therapy. <i>I. T. Tai and A. M. Sun</i>		
Intracellular diversion of glycoprotein GP160 of human immunodeficiency virus to lysosomes as a strategy of AIDS gene therapy. <i>X. Lin, A. Dashti, R. F. Schinazi, and J. Tang</i>		
Regulation of the phosphoenolpyruvate carboxykinase/human factor IX gene introduced into the livers of adult rats by receptor-mediated gene transfer. <i>T. Ferkol, G. L. Lindberg, J. Chen, J. C. Perales, D. R. Crawford, O. D. Ratnoff, and R. W. Hanson</i>		
Hypothesis		
Autoimmune diabetes results from genetic defects manifest by antigen presenting cells. <i>D. V. Serreze</i>		
50 Years Ago		
Basic Medical Sciences and Research 50 Years Ago. <i>W. E. Cornatzer</i>		
Calendar		
BookList		
Employment Opportunities		
New Products & Literature		
Number 12, SEPTEMBER 1993		
Editorial		
Biodiversity—an International Challenge. <i>R. R. Colwell</i>		
News & Features		
BioBits		
Special Feature:		
Biotechnology core facilities: trends and update. <i>K. M. Ivanetich, R. L. Niece, M. Rohde, E. Fowler, and T. K. Hayes</i>		
Serial Review		
Extracellular Matrix 3: Evolution of the extracellular matrix in invertebrates. <i>R. Har-El and M. L. Tanzer</i>		
Reviews		
EPR characterization of molecular targets for NO in mammalian cells and organelles. <i>Y. Henry, M. Lepoivre, J.-C. Drapier, C. Ducrocq, J.-L. Boucher, and A. Guissani</i>		
Biology of free radical scavengers: an evaluation of ascorbate. <i>R. C. Rose and A. M. Bode</i>		
POINT-COUNTERPOINT		
Selective brain cooling in humans: "fancy" or fact? <i>M. Cabanac</i>		
Specialized brain cooling in humans? <i>G. L. Brengelmann</i>		
METHODOLOGY		
Two-dimensional NMR investigations of the interactions of antibodies with peptide antigens. <i>J. Anglister, T. Scherf, B. Zilber, R. Levy, A. Zvi, R. Hiller, and D. Feigelson</i>		
Microcomputer-assisted kinetic modeling of mammalian gene expression. <i>J. L. Hargrove</i>		
Research Communications		
Sigma receptors modulate nicotinic receptor function in adrenal chromaffin cells. <i>J. A. Paul, A. S. Basile, E. Rojas, M. B. H. Youdim, B. De Costa, P. Skolnick, H. B. Pollard, and G. A. J. Kuipers</i>		
Retinoids: in vitro interaction with retinol-binding protein and influence on plasma retinol. <i>R. Berni, M. Clerici, G. Malpeli, L. Cleris, and F. Formelli</i>		
HIV binding to its receptor creates specific epitopes for the CD4/gp120 complex. <i>J. M. Gershoni, G. Denisova, D. Raviv, N. I. Smorodinsky, and D. Buayaner</i>		

1052	Cell cycle control, DNA repair, and initiation of carcinogenesis. <i>W. K. Kaufmann and D. G. Kaufman</i>	1188
	Erratum	1191
1053	50 Years Ago	
	Enzyme Nomenclature: A Personal Retrospective. <i>E. C. Webb</i>	1192
	Calendar	1195
1061	BookList	1196
	Employment Opportunities	1197
1070	New Products & Literature	1199

Number 13, OCTOBER 1993

1081	Editorial	
	<i>Jurassic Park</i> and the "Gay Gene": The New Genetics Seen through the Distorting Lens of the Media. <i>A. S. Wilkins</i>	1203
1092	News & Features	
	BioBits	1205
1097	Special Feature:	
1099	The revolution in communication for biologists—the Internet. <i>A. H. Frey</i>	1206
1100	Communication Capsules	1207
1101	Serial Review	
1105	Extracellular matrix 4: The elastic fiber. <i>J. Rosenbloom, W. R. Abrams, and R. Mecham</i>	1208
	Biogenesis Review	
	Number mysticism in protein thinking. <i>I. M. Klotz</i>	1219
	Reviews	
1107	Astrocytes in infectious and immune-mediated diseases of the central nervous system. <i>L. Mucke and M. Eddleston</i>	1226
1108	Hyaluronan-binding proteins in development, tissue homeostasis, and disease. <i>C. B. Knudson and W. Knudson</i>	1233
	Ischemia: from acidosis to oxidation. <i>R. L. Levine</i>	1242
1109	Aspartylglycosaminuria: protein chemistry and molecular biology of the most common lysosomal storage disorder of glycoprotein degradation. <i>I. Mononen, K. J. Fisher, V. Kaartinen, and N. N. Aronson, Jr.</i>	1247
1113	Trans-sialidase: a unique enzyme activity discovered in the protozoan <i>Trypanosoma cruzi</i> . <i>W. Colli</i>	1257
	Research Communications	
1124	Human immune response to polydimethylsiloxane (silicone): screen- ing studies in a breast implant population. <i>L. E. Wolf, M. Lappé, R. D. Peterson, and E. G. Ezrailson</i>	1265
1135	Expression of nitric oxide synthase by syncytiotrophoblast in human placental villi. <i>K. P. Conrad, M. Vill, P. G. McGuire, W. G. Dail, and A. K. Davis</i>	1269
1143	Vitamin A status and immunoglobulin G subclasses in rats im- munized with tetanus toxoid. <i>M. Kinoshita and A. C. Ross</i>	1277
1148	Use of receptor antibodies to demonstrate membrane glucocorticoid receptor in cells from human leukemic patients. <i>B. Gametchu, C. S. Watson, and S. Wu</i>	1283
1154	Nitric oxide synthesis inhibition induces leukocyte adhesion via superoxide and mast cells. <i>P. Kubes, S. Kanwar, X-F. Niu, and J. P. Gaboury</i>	1293
1163	50 Years Ago	
	Biochemical Teamwork: Revealing the Niacin-Tryptophan Rela- tionship. <i>L. J. Tepley</i>	1300
1171	Calendar	1301
	BookList	1304
1175	Employment Opportunities	1305
	New Products & Literature	1307

1185

Editorial	
Scientists must educate the public that NIH is the principal federal agency that supports biomedical research. <i>S. C. Silver- stein and J. D. Loike</i>	1309
News & Features	
BioBits	1310
Special Feature:	
A statistical model validating triage for the peer review process: keeping the competitive applications in the review pipeline. <i>K. J. Vener, E. J. Feuer, and L. Gorelic</i>	1312
Serial Review	
Extracellular matrix 5: Adhesive interactions in early mammalian embryogenesis, implantation, and placentation. <i>C. Damsky, A. Sutherland, and S. Fisher</i>	1320
Reviews	
Concepts and principles of glycobiology. <i>G. Opdenakker, P. M. Rudd, C. P. Ponting, and R. A. Dwek</i>	1330
Bacterial ice nucleation: significance and molecular basis. <i>D. Gurian-Sherman and S. E. Lindow</i>	1338
Metabolic abnormalities in cobalamin (vitamin B ₁₂) and folate deficiency. <i>R. H. Allen, S. P. Stabler, D. G. Savage, and J. Lindenbaum</i>	1344
Noncholinergic functions of cholinesterases. <i>A. S. Balasubramanian and C. D. Bhanumathy</i>	1354
Proatherosclerotic events: pathobiochemical changes occurring in the arterial wall before monocyte migration. <i>M. Simionescu and N. Simionescu</i>	1359
Chemical nucleases: their use in studying RNA structure and RNA- protein interactions. <i>P. W. Huber</i>	1367
Research Communications	
Lysophosphatidic acid mimics serum-induced sensitization of cyclic AMP accumulation. <i>D. M. Kreps, S. M. Whittle, J. M. Hoffman, and M. L. Toews</i>	1376
Functional and immunological relevance of the COOH-terminal extension of human chorionic gonadotropin β : implications for the WHO birth control vaccine. <i>S. Dirnhöfer, R. Klieber, R. De Leeuw, J.-M. Bidart, W. E. Merz, G. Wick, and P. Berger</i>	1381
Glycogen synthesis in the astrocyte: from glycogenin to proglycogen to glycogen. <i>J. Lomako, W. M. Lomako, W. J. Whelan, R. S. Dombro, J. T. Neary, and M. D. Norenberg</i>	1386
Opposing roles of cyclic AMP in the vascular control of edema formation. <i>J. B. Warren, A. J. Wilson, R. K. Loi, and M. L. Coughlan</i>	1394
A potential pathophysiologic role for $\alpha_2\beta_1$ integrin in human eye diseases involving vitreoretinal traction. <i>T. S. Kupper and T. A. Ferguson</i>	1401
Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. <i>A. Puisieux, K. Galvin, F. Troalen, B. Bressac, C. Marçais, E. Galun, F. Ponchel, C. Yalcier, J. Ji, and M. Ozurk</i>	1407
50 Years Ago	
Rauhsche Nase—Then and Now. <i>A. G. Karczmar</i>	1414
Calendar	1417
BookList	1418
Employment Opportunities	1419
New Products & Literature	1421

Number 15, DECEMBER 1993

Editorial	
Publish or Perish. <i>William J. Whelan</i>	1423
News & Features	
BioBits	1424

Economic impact of applications of monoclonal antibodies to medicine and biology. S. Chishti and S. C. Silverstein	1426	Noninvasive ultrasound techniques versus angiography for monitoring drug-induced changes of the arterial walls. P. Rubba and F. Faccenda	143
Communications Capsules	1431	Research Communications	
Commentary		P-Glycoprotein regulates chemosensitivity in early developmental stages of the mouse. L. Elbling, W. Berger, A. Rehberger, T. Waldhör, and M. Micksche	14
Evaluation of the safety issue of mercury release from dental fillings. F. L. Lorscheider and M. J. Vimy	1432	Modifications of Ca ²⁺ signaling by inorganic mercury in PC12 cells. A. D. Rossi, O. Larsson, L. Manzo, S. Orrenius, M. Vahter, P.-O. Berggren, and P. Nicotera	150
Serial Review		Hypothesis	
Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis. W. G. Steller-Stevenson, L. A. Liotta, and D. E. Kleiner, Jr.	1434	Protein disulfide isomerase is both an enzyme and a chaperone. C.-C. Wang and C.-L. Tsou	151
Biogenesis Review		Acknowledgment	151
Aconitase, a two-faced protein: enzyme and iron regulatory factor. H. Beinert and M. C. Kennedy	1442	50 Years Ago	
Reviews		P/O Ratios—The First Fifty Years. L. Ernster	152
A new family of neurotransmitter transporters: the high-affinity glutamate transporters. Y. Kanai, C. P. Smith, and M. A. Hediger	1450	Calendar	152
Structural-functional correlates of the nicotinic acetylcholine receptor and its lipid microenvironment. F. J. Barrantes	1460	BookList	152
Hepatic glutaminase expression: relationship to kidney-type glutaminase and to the urea cycle. M. Watford	1468	Employment Opportunities	152
Osteopontin: a protein with diverse functions. D. T. Denhardt and X. Guo	1475	New Products & Literature	152
Protein-sulfenic acid stabilization and function in enzyme catalysis and gene regulation. A. Claiborne, H. Miller, D. Parsonage, and R. P. Ross	1483	Subject Index to Volume 7	153
		Author Index to Volume 7	153

Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis

AARON J. MARCUS¹ AND LENORE B. SAFIER

Thrombosis Research Laboratory, Divisions of Hematology/Oncology, Departments of Medicine and Pathology, Department of Veterans Affairs Medical Center, and Cornell University Medical College, New York, New York, USA

ABSTRACT Blood platelets represent the first line of host defense when normal vessels are injured. Platelet adhesion to subendothelium, aggregation, and further platelet recruitment culminate in hemostatic plug formation, which is accompanied by the consolidating effect of fibrin deposition on and between platelets. The process is multicellular in that erythrocytes promote and neutrophils inhibit platelet plug formation. Endothelial cells in proximity possess three protective mechanisms (thromboregulators) for limiting the size of the hemostatic plug—ADPase, eicosanoids, endothelium-dependent relaxing factor/NO. We propose that in advanced atherosclerotic blood vessels such as coronary arteries, an ulcer or fissure in the fibrous cap of the atheroma serves as an agonist that transforms the platelet into a major prothrombotic offender. Induction of excessive platelet activation overcomes the normal thromboregulatory mechanisms. Erythrocytes further activate platelets, even in the presence of aspirin, and neutrophil blockage of platelet reactivity is insufficient to prevent impending vascular occlusion. Appreciating that multiple cell types and metabolic pathways are involved in modulation of platelet reactivity in vascular occlusion is a relatively recent concept. Strategies designed to restore processes such as thromboregulation may serve to improve therapeutics in thrombosis, which at present is far from optimal.—Marcus, A. J.; Safier, L. B. Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis. *FASEB J.* 7: 516–522; 1993.

Key Words: platelet activation and recruitment • transcellular metabolism • endothelial cell-platelet interactions • erythrocyte-platelet interactions • neutrophil-platelet interactions • endothelial ecto-ADPase • EDRF/NO

WHEN THE CONTINUITY OF A NORMAL blood vessel is interrupted, the initial response to the injury is defined as primary hemostasis (1). Superimposed on an intense vasoconstriction is the process of platelet activation. Platelets immediately adhere to collagen in the subendothelium that has been exposed by the injury. Collagen is a strong platelet agonist that induces platelet activation, leading to secretion of additional agonists. These include ADP, thromboxane (TXA₂),² and serotonin (5-HT). Secretion leads to recruitment of other platelets that aggregate upon the initial layer of adherent platelets, thereby forming the hemostatic plug (Fig. 1). Activated platelets also undergo a change in shape from a disk to a spiny sphere. In the process, rearrangement of membrane phospholipoprotein components forms a catalytic procoagulant surface. Activated coagulation factor X is bound to the platelet surface in the presence of activated factor V. Factor VII of the extrinsic coagulation system is also

platelet surface-activated (1). These interactions culminate in formation of thrombin, which is the catalyst for fibrin transformation from fibrinogen, as well as being another strong platelet agonist. The thrombin-mediated reinduction of platelet activation and recruitment, along with coagulation, defines secondary hemostasis. The hemostatic platelet plug is now consolidated and impermeable as evidenced by complete cessation of hemorrhage (1). Thus, platelets form the nidus of a structure that withstands the back pressure induced by cardiac output. However, other cells are participating as promoters or inhibitors of platelet reactivity. The plug remains localized through this extracellular and fluid phase protein inhibitory activity as well as inhibitory mechanisms intrinsic to the platelet (2) (Fig. 1).

In contrast to normal hemostasis in injured but otherwise healthy vessels, arterial thrombosis in diseased vessels can be interpreted as a misdirected or abnormal consequence of the normal process. Although thrombi resemble hemostatic plugs morphologically (3), their development differs from that of hemostatic plugs in at least one important aspect. An arterial thrombus almost always occurs at sites of pathologic vascular damage. A major offender is the deeply fissured or ulcerated advanced atherosclerotic plaque in the vessel wall, which may contain an eroded fibrous cap with lipid-rich necrotic tissue and inflammatory cells (4–6). The agonistic potential of such lesions promotes far more platelet adhesion, activation, recruitment, and consolidation than an injured healthy vessel surface. In addition, lipid-rich arterial plaques are a nidus for intermittent thrombus formation due to recurrent fissuring as well as slow release of incorporated thrombin (5, 7, 8). The size of pathologic thrombi and the extent of associated normal tissue damage often surpass the capacity of normal control mechanisms. These pathologic thrombi can then extend or embolize to totally occlude vessels, leading to ischemia and death. The multiple factors involved in induction of arterial thrombosis and the associated myofibrotic response probably account for the difficulty in clinical management of these occlusive events (Fig. 2).

Several cell types in the microvasculature can modulate the growth of platelet thrombi. Microscopic time course studies of evolving thrombi initially demonstrate platelets adherent to subendothelium. The central core of the platelet

¹To whom correspondence should be addressed, at: Thrombosis Research Laboratory, Room 13028W, Department of Veterans Affairs Medical Center, 423 East 23rd St., New York, NY 10010, USA.

²Abbreviations: TXA₂, thromboxane; 5-HT, serotonin; PGH₂, prostaglandin H₂; EDRF/NO, endothelium-dependent relaxing factor/nitric oxide; PGI₂, prostacyclin, prostaglandin I₂; 12-HETE, 12-hydroxyeicosatetraenoic acid; G protein, guanosine triphosphate-binding regulatory protein.




Figure 1. Diagrammatic representation of the normal hemostatic process. *A*) Exposure of subendothelium due to vascular damage results in immediate platelet adherence to collagen, basement membrane and microfibrils in the presence of von Willebrand factor and platelet membrane glycoprotein Ib. The strong platelet agonist, collagen, induces release of ADP and serotonin (5-HT) from dense granules and several proteins from alpha granules. The eicosanoid thromboxane A₂ is also formed enzymatically from free arachidonic acid. Simultaneously, endothelial cell defense mechanisms (thromboregulators) become functional to limit the size of the thrombus. Concomitantly with formation of the releasate, the recruitment phase is initiated. *B*) ADP, 5-HT, and TXA₂ are the most important recruiting components of the platelet releasate. They activate additional platelets arriving in the fluid phase, which then undergo shape change and aggregate onto the initial layer of activated platelets. Thromboxane and serotonin also induce vasoconstriction, which serves to limit the velocity of blood flow. Phospholipoproteins are now available on the platelet surface for catalytic activation of proteins of the coagulation system. *C*) Thrombin formation has several major consequences which lead to the final stages of platelet thrombus development. Platelet activation, release, and recruitment are reinduced and fibrin formation is initiated. Fibrin strands begin to intercalate between activated platelets and the thrombus becomes consolidated. *D*) The consolidated platelet thrombus is now virtually impermeable and its multicellular nature becomes obvious. There is in vitro and ex vivo evidence that intact metabolically viable erythrocytes are prothrombotic in that they increase the reactivity of activated platelets (12). Neutrophils are also seen in close contact with platelets. The modest chemotactic activity of released platelet 12-HETE may contribute to the arrival of the neutrophils. Platelet-neutrophil contact may be due to the adhesive platelet glycoprotein, P-selectin, interacting with its receptor on the neutrophil surface (33, 34). The neutrophil also down-regulates platelet reactivity and therefore may serve as an important antithrombotic modality (14). Formation of the platelet thrombus also signals the initiation of fibrinolysis, i.e., release of tissue plasminogen activator (TPA) from endothelial cells. (Adapted from Dr. J. F. Mustard with permission.)

thrombus gradually becomes admixed with erythrocytes, neutrophils, and subsequently, occasional monocytes. In addition to the aforementioned cells, there are normal metabolically viable endothelial cells adjacent to the lesion. For many years the presence of multiple cells in a thrombus was thought to represent a passive, random phenomenon. However, biochemical and functional interactions between platelets and other cells have been definitively demonstrated in vitro (9, 10) and there is strong evidence for their occurrence in vivo (11). Many of these interactions are thromboregulatory in that they culminate in enhancement or inhibition of platelet reactivity. For example, intact erythrocytes in close proximity to activated platelets markedly enhance

platelet reactivity (12, 13). In sharp contrast, neutrophils (14) and endothelial cells (15-17) inhibit platelet activation and recruitment, thereby possibly limiting the size of the thrombus. As will be discussed, these interactions occur in the setting of cell proximity or direct contact. They can be due to secretory products of one or more cell types after activation by a specific agonist (or agonists) or to surface-connected modulators. In some circumstances, transcellular metabolism occurs in which the product of one cell is transformed by another. This can even result in the formation of a metabolite that cannot be synthesized by either cell alone. Occurrences of this phenomenon have thus far been demonstrated in vitro between platelets and endothelial cells, neu-




Figure 2. Progression of coronary atherogenesis to thrombogenesis on the pathologic and clinical level. Early lesions contain macrophages and lipid droplets. These progress to involve smooth muscle and a fibrotic lipid core. As the lesions progress to stage V they develop fissures and ulcerate. Intraluminal thrombi form and this constitutes the complicated plaque, eventually leading to the acute coronary syndromes. Repeated mural thrombi, initiated by activated platelets, result in progression of the atherosclerotic process. These concepts emphasize that atherogenesis and thrombogenesis should be studied in parallel. (Reviewed in ref 5.)

trophils, erythrocytes, and smooth muscle cells (9). These studies from our own and other laboratories suggest that the development and possible reversibility of thrombosis represent an integrated group of multicellular biochemical events (9).

BASIC BIOCHEMICAL PARAMETERS OF PLATELET REACTIVITY

Significant advances have been made in our comprehension of the biochemical events in platelet activation (2, 18). These mechanisms will be briefly summarized. Biochemically, the initial event in platelet activation is binding of an agonist such as thrombin to the extracellular domain of a specific platelet membrane receptor (19). As in other cells, platelet receptors for agonists and inhibitors are transmembrane proteins with cell surface and cytoplasmic components. The signal, initiated by receptor occupancy, is then transmitted by the cytoplasmic domain of the receptor, frequently through guanosine triphosphate-binding regulatory proteins (G proteins), to membrane-bound, signal-generating enzymes such as phospholipase C (Fig. 3). Activation of these enzymes induces generation of second messenger molecules. For example, phospholipase C initiates the phosphoinositide pathway of activation via hydrolysis of the membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PIP₂). This gives rise to two platelet second messengers, inositol 1,4,5-trisphosphate (IP₃) and diacylglycerol (DG). IP₃ induces calcium release from the platelet dense tubular system. A rise in free calcium in the cytosol is a critically important aspect of platelet activation and consequent events. Diacylglycerol activates protein kinase C, which in turn promotes protein phosphorylation, platelet granule secretion, and expression of the fibrinogen receptor on the platelet surface. Platelet

cytoskeletal rearrangements that occur during platelet activation may be involved in granule secretion. As mentioned, the ADP released from platelet dense granules is important for recruitment of additional platelets to the thrombus. The fibrinogen receptor site is on the platelet membrane glycoprotein IIb-IIIa complex, which becomes transformed during platelet activation to assume its receptor function. The latter glycoproteins belong to the integrin group of adhesive protein receptors. By interacting with its receptors, fibrinogen forms a bridge between platelets in proximity, thereby resulting in platelet aggregation/cohesion (18).

A second important pathway in platelet activation is also initiated by enzymatic hydrolysis of a membrane phospholipid. Arachidonate, an essential fatty acid, is cleaved from phospholipid largely via catalysis by phospholipase A₂. Activation of this enzyme has been reported to involve several entities including the rise in free cytosolic calcium occurring during platelet activation, membrane Na⁺/H⁺ exchange, and one or more G proteins. Arachidonate cleavage can also result from combined actions of phospholipase C and diacylglycerol lipase (Fig. 3). Some arachidonate is released to the exterior of the platelet where it can be taken up by other cells and become involved in transcellular metabolism. In the cytosol, arachidonate is enzymatically oxygenated by cyclooxygenase and 12-lipoxygenase. The major biologically active platelet cyclooxygenase product formed by way of its transient intermediate, endoperoxide PGH₂, is thromboxane A₂ (TXA₂). This autacoid is released, acts as a vasoconstrictor, and takes part in the recruiting process via a platelet membrane receptor (Fig. 3).

CONTROL OF PLATELET REACTIVITY BY ENDOTHELIAL CELLS

Platelets in the circulation are not activated as long as the endothelium remains biochemically and physically intact. Actually, platelets produce a substance (or substances) that maintains the integrity of the vasculature and prevents spontaneous hemorrhage (1). When platelets do become activated as a consequence of injury, endothelial cells respond in a manner that is directed toward limitation or reversal of the consequences of platelet reactivity. This response can be defined as *endothelial thromboregulation*.

Thromboregulation is amenable to study in vitro. This is done with combined suspensions of cultured human umbilical cord endothelial cells and human platelets in motion in aggregometer cuvettes (15). Thus, maximal cell density is achieved and both functional and biochemical parameters can be measured simultaneously. Platelets become unresponsive to agonists in the presence of endothelial cell suspensions and this is due to at least three separate endothelial thromboregulatory systems. These include the eicosanoids, endothelium-dependent relaxing factor (now thought to be nitric oxide) (EDRF/NO), and the ecto-nucleotidase ATP-diphosphohydrolase (ATPDase), which has both ADP-ase and ATP-ase activities (17, 20-22).

Eicosanoids

The arachidonate pathway in endothelial cells can be initiated by agonists such as thrombin. The major product of eicosanoid metabolism in these cells is PGI₂, formed from the same endoperoxide PGH₂, which in platelets gives rise to TXA₂. Released endothelial cell PGI₂ can react with the platelet surface domain of a specific receptor, thereby initiating a G protein-linked signal transduction pathway of the




Figure 3. Signal transduction during platelet activation. The binding of agonists to membrane-spanning receptors on the platelet surface initiates cascades of intracellular second messengers, including inositol 1,4,5-trisphosphate (IP_3) and diacylglycerol (DG). IP_3 releases Ca^{++} from the platelet dense tubular system, raising the cytosolic free Ca^{++} concentration. Diacylglycerol activates the serine/threonine kinase, protein kinase C, translocating it to the plasma membrane and triggering granule secretion and fibrinogen receptor exposure on the glycoprotein IIb-IIIa complex. At the same time, the rising cytosolic free Ca^{++} concentration facilitates arachidonate (AA) release from phospholipids by phospholipase A_2 , a process that may occur at both the plasma membrane and the dense tubular system membrane. Arachidonate is metabolized to thromboxane A_2 (TxA_2), which diffuses out of the cell, interacts with receptors on the platelet surface, and causes further platelet activation. At some point during this process, tyrosine kinases, including members of the src family, are activated in platelets and cause the phosphorylation on tyrosine of multiple platelet proteins, most of which have not been identified. Tyrosine kinase activation in platelets appears to occur predominantly as a consequence of fibrinogen receptor expression and platelet aggregation, but can also occur as an early step in platelet activation. In many cases, the interactions between agonists and the enzymes responsible for second messenger generation are mediated by a guanine nucleotide-binding regulatory protein (G protein). In platelets, G proteins have been shown to regulate phosphoinositide hydrolysis and cAMP formation, and are probably involved in the activation of phospholipase A_2 . Phospholipase C (presumably phospholipase C_β) is activated in a pertussis toxin-sensitive manner by the still-unidentified G protein, G_p , and in a pertussis toxin-resistant manner by the G protein, G_q . Adenylyl cyclase is stimulated by the G protein, G_s , and inhibited by the G protein, G_i . The G protein that regulates phospholipase A_2 activity remains to be characterized. Platelet receptors for thrombin, epinephrine, thromboxane A_2 , and platelet activating factor have been cloned and shown to resemble other G protein-coupled receptors with a characteristic structure comprised of a single polypeptide with seven transmembrane domains. The low molecular weight GTP-binding protein, *rap1B*, has recently been shown to form a complex with phospholipase C_γ and *ras*-GAP, supplying a potential mechanism for regulating phospholipase C_γ activity. Other low molecular weight GTP-binding proteins may be involved in the regulation of vesicular transport and granule secretion in platelets. Provided by Dr. Lawrence F. Brass (18).

type described for activation of phospholipase C. In this case, the signal-generating enzyme is adenylyl cyclase. The latter catalyzes formation of the second messenger cAMP from ATP (Fig. 3). In contrast to other cells where it promotes reactivity, cAMP is a strong inhibitor of platelet function. cAMP antagonizes calcium-mediated responses by a variety of mechanisms (2). Effects of cAMP are generally thought to be mediated by a cAMP-dependent protein kinase (or kinases) (2).

Through a process of transcellular metabolism between platelets and endothelial cells, greater quantities of PGI_2 can be generated than can be synthesized by endothelial cells alone (15, 23). This is demonstrable by radiolabeling platelets with arachidonate and combining them with aspirin-treated, unlabeled endothelial cells that are incapable of producing endogenous endoperoxide PGH_2 . Stimulation of these combined suspensions with thrombin, collagen, or ionophore results in production of radiolabeled prostacyclin

plus other eicosanoids. The labeled PGH_2 intermediate required for formation of labeled PGI_2 can only originate from the labeled platelets. These results can be confirmed using unlabeled platelets and unlabeled endothelial cells, both of which have not been aspirin-treated. Prostacyclin is quantified by radioimmunoassay. In this system wherein endothelial cells produce PGI_2 endogenously as well as from platelet endoperoxides, more PGI_2 is synthesized than the endothelial cells can produce alone.

Endothelium-dependent relaxing factor/nitric oxide (EDRF/NO)

EDRF is an aspirin-insensitive fluid-phase autacoid produced by vascular endothelium and a large variety of other cells. It is identical with nitric oxide or a related nitrosyl compound. NO is the active principle of the group of compounds known as nitrovasodilators (24), and its mode of ac-

tion is via specific stimulation of the -containing soluble guanylyl cyclase in target cells. The resulting elevation of cyclic GMP blocks responsiveness of activated platelets. This inhibition is independent of that induced by cyclic AMP, but the two phenomena may be synergistic. In endothelial cells, NO is produced constitutively from L-arginine by the action of a calcium/calmodulin and NADPH-dependent NO synthase. In addition, NO has been identified in the central nervous system where it acts as a neurotransmitter, and in macrophages, where it is bacteriocidal (24-27).

Because EDRF/NO is a gas with a half-life of approximately 5 s, it is difficult to study in vitro. However, the system previously described for studying combined suspensions of endothelial cells and platelets in close contact is particularly suitable for this purpose. Both cell types can be aspirin-treated to inhibit PGI₂ formation, and inhibition of platelet aggregation can be readily demonstrated. Reversal of this inhibition by antagonists of EDRF formation and function can also be evaluated. Using this system, Broekman et al. (16) demonstrated EDRF/NO regulation of human platelet reactivity by cultured human endothelial cells. Platelet aggregation and serotonin release are inhibited in parallel in this aspirin-treated system. The endothelial cell-derived EDRF/NO activity is enhanced by superoxide dismutase, and reversed by hemoglobin and by competitive inhibitors of arginine metabolism such as derivatives of L-arginine with modified guanidino groups. When platelets and endothelial cells are separated by a permeable membrane and both cells stimulated by thrombin, the platelets remain unresponsive. Therefore the inhibition observed has been induced by a fluid-phase mediator in the absence of cell contact.

The significance of EDRF/NO as a major control system for vasomotor activity, platelet adhesion, and aggregation is becoming more apparent. Deficient EDRF/NO activity has been reported in atherosclerotic blood vessels, hypertension, vascular occlusion, and reperfusion injury (24).

Endothelial cell ecto-nucleotidase activity

The third endothelial thromboregulatory mechanism involves ecto-nucleotidases on the cell surface. Until recently, nucleotides were thought to serve mainly as intracellular energy sources. It is now appreciated that nucleotides can be released in response to cell activation or injury, and through specific receptors may elicit biological responses, some of which can be deleterious. An example of the latter would be the prothrombotic effects of excessive ADP release from platelets and injured tissues (28). The endothelial cell membrane thromboregulatory ecto-nucleotidases are aspirin-insensitive enzymes that metabolize released platelet ADP to AMP and adenosine, thereby limiting platelet recruitment (17).

ADPase activity is demonstrable in the in vitro aggregometry system described above for studying platelet-endothelial cell interactions. EDRF/NO effects and PGI₂ production by endothelial cells under study are blocked by simultaneous treatment with hemoglobin and aspirin, respectively. Nevertheless, in this setting inhibition of platelet responsiveness by

endothelial cells persists. This is observed by both aggregometry and measurement of platelet serotonin release. Such inhibition is largely due to ecto-ADPase activity on the endothelial cells. This can be established biochemically by incubating aspirin-treated endothelial cells with [¹⁴C]ADP. Radio thin layer chromatography and aggregometry demonstrates a correlation between [¹⁴C]ADP catabolism and loss of platelet stimulatory activity in the supernatant fluid. AMP accumulates transiently and is further metabolized to adenosine. The latter further inhibits platelet reactivity by elevating cAMP levels. An ADPase activity has been localized in the membrane fraction of human endothelial cells and is soluble in Triton X-100-ethylene glycol. Enzyme activity is detectable on polyacrylamide gels run in Triton, with a lead sulfide stain. The same protein band can hydrolyze ATP as well as ADP (21). Therefore the enzyme is an apyrase or ATP-diphosphohydrolase (ATPDase) (20).

Thus, at the present time there is in vitro evidence for at least three independent endothelial cell regulatory systems for platelet reactivity. As experimental horizons broaden and appropriate detection systems evolve, additional antithrombotic endothelial cell control systems may be identified. Only a few short years ago all the platelet inhibitory activity attributable to endothelial cells was thought to be due to prostacyclin alone. We now know that this is not the case. Table 1 summarizes properties of the regulatory systems discussed.

ENHANCEMENT OF PLATELET REACTIVITY BY INTACT ERYTHROCYTES

Erythrocytes have long been known to play a role in hemostasis. Anemic patients have prolonged bleeding times that normalize upon correction of the erythrocyte deficit. It has been demonstrated that intact erythrocytes promote biochemical and functional responsiveness of activated platelets (12, 13). The platelet-erythrocyte interaction was carried out using a novel two-stage procedure. This permitted studies of cell-cell interactions and independent evaluation of platelet activation and recruitment within 1 min of stimulus addition. This assay system differs markedly from those usually used to study cell-cell interactions wherein cells are incubated together, the agonist is added, and results in the combined suspension monitored over a prolonged period of time. In the activation-recruitment assay, agonists are added to combined suspensions of platelets and erythrocytes and a cell-free releasate is prepared within 1 min. This releasate is then studied biochemically and is also added to a separate platelet preparation where it is tested for enhancing or inhibitory effects on aggregation. This in vitro action of the releasate serves as a prototype for the platelet recruitment process (12, 13).

Releasates obtained from mixtures of erythrocytes and platelets contain higher concentrations of secreted ADP (13) and induce greater aggregation (recruitment) than those ob-

TABLE 1. Inhibitory thromboregulators associated with human endothelial cells

Class	Type	Site of action	Aspirin sensitivity	Mode of action
Eicosanoids	PGI ₂ , PGD ₂	Fluid phase autacoid	Inhibited	Elevation of platelet cAMP
Nitrovasodilators	EDRF/NO	Fluid phase autacoid	Insensitive	Elevation of platelet cGMP
Ecto-nucleotidases	ATPDase	Endothelial cell surface	Insensitive	Enzymatic removal of secreted ADP

tained from platelets alone. The erythrocytes remain capable of increasing platelet serotonin release (activation) despite aspirin treatment, enzymatic removal of released ADP, protease inhibition, or combinations of the above. An in vivo counterpart of these results is the possibility that erythrocyte enhancement of platelet reactivity can reduce the therapeutic effectiveness of aspirin. Erythrocytes also promote increased platelet arachidonate release and eicosanoid formation. Platelet stimulation with collagen or thrombin in the presence of erythrocytes results in significant increases in cyclooxygenase and lipoyxygenase metabolites. In addition, activated platelet-erythrocyte mixtures with or without aspirin promote 3- to 10-fold increases in extracellular free arachidonate. The latter is available for transcellular metabolism in other cell types (12, 13). For example, released platelet arachidonate can be taken up by a stimulated neutrophil in proximity to form leukotriene B₄, the most proinflammatory eicosanoid yet described. In this way platelets play an indirect role in the inflammatory response.

The precise mechanism (or mechanisms) underlying erythrocyte enhancement of platelet reactivity has not as yet been delineated. The in vitro data on platelet activation and recruitment discussed here suggest that at least two separate events are occurring: Stimulated platelets activate a process in the intact erythrocyte, which causes the erythrocyte to further activate the platelet. The end result of this cell-cell communication is a prohemostatic and prothrombotic erythrocyte effect.

NEUTROPHILS DOWN-REGULATE HUMAN PLATELET REACTIVITY

Because the activation-recruitment system described above serves as an in vitro model for early cellular and biochemical events in thrombosis, it was used to study platelet-neutrophil interactions as well. During hemostasis, thrombosis, and the inflammatory response, the proximity of platelets and neutrophils allows for modulation of each others' activity. For example, we know that released platelet 12-HETE can be processed by unstimulated neutrophils to 12,20-DiHETE and 12-HETE-1,20-dioic acid, and by stimulated neutrophils to 5,12-DiHETE (29-32). On the other hand, the activation-recruitment system demonstrates that unstimulated neutrophils can modulate aggregation and secretion in stimulated platelets. When combined suspensions of normal numbers of neutrophils and platelets are stimulated by collagen or thrombin, platelet serotonin release and the proaggregatory activity of cell-free releasates from the mixture are markedly decreased (14). In these experiments, neutrophil serine proteases and EDRF/NO formation are not involved in the inhibitory activity. In the case of collagen, about 29% of the neutrophil inhibitory effect is attributable to ecto-ADPase activity, but this is not the major cause of the inhibition.

When cell-cell interactions are studied in the activation-recruitment system, the platelets and neutrophils are brought into close cell contact during the centrifugation step. Furthermore, upon platelet activation the adhesive protein P-selectin is expressed on the platelet surface, where it mediates adhesion to neutrophils (33, 34). It was important to discern whether P-selectin-mediated platelet-neutrophil adhesion was necessary for the inhibitory effect of neutrophils on platelets to occur. This question was examined with specific monoclonal antibodies to P-selectin, which blocked platelet-neutrophil adhesion. It is interesting that neutrophil inhibition of platelet reactivity was actually enhanced when adhe-

sion was blocked. Neutrophils are more effective in controlling platelet reactivity when the cells are not metabolically adherent to each other. We propose that P-selectin acts in a prothrombotic manner because of its ability to reverse neutrophil inhibition of platelet reactivity.

Comparable results were obtained with the platelet 12-lipoxygenase product (12-HETE) or its derivatives originating from transcellular metabolism between platelets and unstimulated neutrophils. Like P-selectin, these lipoxygenase products reduced the inhibitory effect of neutrophils when the platelets were activated by thrombin (14).

In addition to participating in the inflammatory response accompanying the thrombotic process, neutrophils play a regulatory role. By inhibiting platelet reactivity, neutrophils may serve to limit the size and extent of the thrombus. Also, we do not know the precise functional implications of neutrophil metabolism of platelet lipoxygenase products. The process is efficient and well regulated and its significance may become more apparent when the properties of lipoxygenase-type eicosanoids are further elucidated (30, 31).

In summary, in vitro studies from many laboratories strongly suggest that thrombosis represents an integrated group of multicellular events. These events involve metabolic and functional interactions between platelets, endothelial cells, erythrocytes, and neutrophils. Future approaches to the pathogenesis and treatment of thrombosis will need to consider therapy that will affect more than one cell type and methods for enhancing activity of newly recognized thromboregulators. [F]

We would like to acknowledge the outstanding research contributions of Drs. Teresa Santos, Juana Valles, and M. Johan Broekman toward the concepts presented herein. We also thank Ms. Evelyn M. Ludwig for her expert editorial collaboration in the preparation of this article. Supported by grants from the Department of Veterans Affairs and the National Institutes of Health (HL-18828, HL-46403 and HL-47073).

REFERENCES

1. Marcus, A. J. (1990) In *Disorders of Hemostasis* (Ratnoff, O. D. and Forbes, C. D., eds) pp. 75-140, Grune & Stratton, New York
2. Kroll, M. H., and Schafer, A. I. (1989) Biochemical mechanisms of platelet activation. *Blood* 74, 1181-1195
3. Woolf, N. (1992) In *Oxford Textbook of Pathology* (McGee, J. O'D., Isaacson, P. G., and Wright, N. A., eds) pp. 509-519, Oxford University Press, New York
4. Myler, R. K., Frink, R. J., Shaw, R. E., Bashour, T. T., Hecht, H. S., Ryan, C., Cumberland, D. C., and Stertz, S. H. (1990) The unstable plaque: pathophysiology and therapeutic implications. *J. Invas. Cardiol.* 2, 117-128
5. Fuster, V., Badimon, L., Badimon, J. J., and Chesebro, J. H. (1992) The pathogenesis of coronary artery disease and the acute coronary syndromes. *N. Engl. J. Med.* 326, 242-250; 310-318
6. Stary, H. C. (1989) Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. *Arteriosclerosis* 9, 1-19-1-32
7. Davies, M. J. (1990) A macro and micro view of coronary vascular insult in ischemic heart disease. *Circulation* 82, II-38-II-46
8. Szczeklik, A., Dropinski, J., Radwan, J., and Krzanowski, M. (1992) Persistent generation of thrombin after acute myocardial infarction. *Arterioscler. Thromb.* 12, 548-553
9. Marcus, A. J. (1990) Thrombosis and inflammation as multicellular processes. Pathophysiological significance of transcellular metabolism. *Blood* 76, 1903-1907
10. Macclouf, J., Fitzpatrick, F. A., and Murphy, R. C. (1989) Trans-

- cellular biosynthesis of eicosanoids. *Pharmacol. Res.* 21, 1-7
11. Brezinski, D. A., Nesto, R. W., and Ullman, C. N. (1992) Angioplasty triggers intracoronary leukotrienes and lipoxin A₄. Impact of aspirin therapy. *Circulation* 86, 56-63
12. Santos, M. T., Valles, J., Marcus, A. J., Safier, L. B., Broekman, M. J., Islam, N., Ullman, H. L., Eiroa, A. M., and Aznar, J. (1991) Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. *J. Clin. Invest.* 87, 571-580
13. Valles, J., Santos, M. T., Aznar, J., Marcus, A. J., Martinez-Sales, V., Portoles, M., Broekman, M. J., and Safier, L. B. (1991) Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, ADP release, and recruitment. *Blood* 78, 154-162
14. Santos, M. T., Valles, J., Marcus, A. J., Safier, L. B., Broekman, M. J., Islam, N., Ullman, H. L., and Eiroa, A. M. (1991) Contrasting effects of 12- and 5-lipoxygenase products in the inhibition of human platelet reactivity by neutrophils. *Clin. Res.* 39, 254a (abstr.)
15. Marcus, A. J., Weksler, B. B., Jaffe, E. A., and Broekman, M. J. (1980) Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. *J. Clin. Invest.* 66, 979-986
16. Broekman, M. J., Eiroa, A. M., and Marcus, A. J. (1991) Inhibition of human platelet reactivity by endothelium-derived relaxing factor from human umbilical vein endothelial cells in suspension. Blockade of aggregation and secretion by an aspirin-insensitive mechanism. *Blood* 78, 1033-1040
17. Marcus, A. J., Safier, L. B., Hajjar, K. A., Ullman, H. L., Islam, N., Broekman, M. J., and Eiroa, A. M. (1991) Inhibition of platelet function by an aspirin-insensitive endothelial cell ADPase. Thromboregulation by endothelial cells. *J. Clin. Invest.* 88, 1690-1696
18. Brass, L. F. (1991) In *Hematology. Basic Principles and Practice* (Hoffman, R., Benz, E. J., Jr., Shattil, S. J., Furie, B., and Cohen, H. J., eds) pp. 1176-1197, Churchill Livingstone, New York
19. Coughlin, S. R., Vu, T.-K. H., Hung, D. T., and Wheaton, V. I. (1992) Characterization of a functional thrombin receptor. Issues and opportunities. *J. Clin. Invest.* 89, 351-355
20. Côté, Y. P., Filep, J. G., Battistini, B., Gauvreau, J., Sirois, P., and Beaudoin, A. R. (1992) Characterization of ATP-diphosphohydrolase activities in the intima and media of the bovine aorta: evidence for a regulatory role in platelet activation in vitro. *Biochim. Biophys. Acta Mol. Basis Dis.* 1139, 133-142
21. Marcus, A. J., Safier, L. B., Hajjar, K. A., Ullman, H. L., Islam, N., Broekman, M. J., and Eiroa, A. M. (1992) Thromboregulatory activity of cultured human endothelial cells: sub-cellular localization and solubilization of a membrane ADPase. *Clin. Res.* 40, 226A (abstr.)
22. Yagi, K., Shinbo, M., Hashizume, M., Shimba, L. S., Kurimura, S., and Yamaoka, Y. (1991) ATP diphosphohydrolase is responsible for ecto-ATPase and ecto-ADPase activities in bovine aorta endothelial and smooth muscle cells. *Biochem. Biophys. Res. Commun.* 180, 1200-1206
23. Schafer, A. I., Crawford, D. D., and Gimbrone, M. A., Jr. (1984) Unidirectional transfer of prostaglandin endoperoxides between platelets and endothelial cells. *J. Clin. Invest.* 73, 1105-1112
24. Bassenge, E. (1992) Clinical relevance of endothelium-derived relaxing factor (EDRF). *Br. J. Clin. Pharmacol.* 34 (Suppl. 1), 37S-42S
25. Moncada, S., Palmer, R. M. J., and Higgs, E. A. (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. *Pharmacol. Rev.* 43, 109-142
26. Ignarro, L. J. (1991) Signal transduction mechanisms involving nitric oxide. *Biochem. Pharmacol.* 41, 485-490
27. Nathan, C. (1992) Nitric oxide as a secretory product of mammalian cells. *FASEB J.* 6, 3051-3064
28. Côté, Y. P., Picher, M., St-Jean, P., Béliveau, R., Potier, M., and Beaudoin, A. R. (1991) Identification and localization of ATP-diphosphohydrolase (apyrase) in bovine aorta: relevance to vascular tone and platelet aggregation. *Biochim. Biophys. Acta* 1078, 187-191
29. Marcus, A. J., Broekman, M. J., Safier, L. B., Ullman, H. L., Islam, N., Serhan, C. N., Rutherford, L. E., Korchak, H. M., and Weissmann, G. (1982) Formation of leukotrienes and other hydroxy acids during platelet-neutrophil interactions in vitro. *Biochem. Biophys. Res. Commun.* 109, 130-137
30. Marcus, A. J., Safier, L. B., Ullman, H. L., Broekman, M. J., Islam, N., Oglesby, T. D., and Gorman, R. R. (1984) 12S,20-Dihydroxyicosatetraenoic acid: a new eicosanoid synthesized by neutrophils from 12S-hydroxyicosatetraenoic acid produced by thrombin- or collagen-stimulated platelets. *Proc. Natl. Acad. Sci. USA* 81, 903-907
31. Marcus, A. J., Safier, L. B., Ullman, H. L., Islam, N., Broekman, M. J., and von Schacky, C. (1987) Studies on the mechanism of ω -hydroxylation of platelet 12-hydroxyicosatetraenoic acid (12-HETE) by unstimulated neutrophils. *J. Clin. Invest.* 79, 179-187
32. Marcus, A. J., Safier, L. B., Ullman, H. L., Islam, N., Broekman, M. J., Falck, J. R., Fischer, S., and von Schacky, C. (1988) Platelet-neutrophil interactions. (12S)-hydroxyicosatetraen-1,20-dioic acid: a new eicosanoid synthesized by unstimulated neutrophils from (12S)-20-dihydroxyicosatetraenoic acid. *J. Biol. Chem.* 263, 2223-2229
33. Larsen, E., Celi, A., Gilbert, G. E., Furie, B. C., Erban, J. K., Bonfanti, R., Wagner, D. D., and Furie, B. (1989) PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. *Cell* 59, 305-312
34. McEver, R. P. (1991) Leukocyte interactions mediated by selectins. *Thromb. Haemostas.* 66, 80-87